SCCA Lymphoma Clinical Trials

This pilot clinical trial studies brentuximab vedotin in treating patients with relapsed or refractory cluster of differentiation (CD)30+ lymphoma. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing

• Relapsed or refractory CD30+ lymphoma that has either achieved < PR to brentuximab vedotin (minimum of 2 cycles) or progressed while receiving brentuximab vedotin
• Documented expression of CD30 on tumor cells following the last dose of brentuximab vedotin
• Absolute neutrophil count (ANC) > 1,000/uL
• Platelets > 50,000/uL
• Serum creatinine < 1.5 mg/dL OR creatinine clearance > 60 mL/min
• Bilirubin < 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
• Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> 1.5 cm)
• Resolution of all non-hematologic brentuximab vedotin-related adverse events (AEs) to < Grade 2
• All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
• Patients must be anticipated to complete at least 2 cycles of chemotherapy on study
• Expected survival if untreated of > 90 days

• Prior transplant within 100 days
• Radioimmunotherapy within 12 weeks
• Known human immunodeficiency virus (HIV) or hepatitis B positivity
• Active infection or other medical condition which would preclude treatment in the opinion of the principal investigator
• Eastern Cooperative Oncology Group (ECOG) performance status > 2
• Known active central nervous system (CNS) involvement
• Peripheral neuropathy > Grade 1 if due to brentuximab vedotin or any peripheral neuropathy > Grade 2
• Intolerance to brentuximab vedotin
• Concurrent use of other anti-cancer agents or experimental treatments